View Older Stories

Oct 5, 2026 12:21PM RBC Capital maintains Outperform rating on Insmed amid CFO change

Sep 24, 2026 05:34AM Goldman Sachs Assumes Insmed (INSM) at Buy

Sep 22, 2026 09:04AM Mizuho on Insmed (INSM): 'seeing attractive risk/reward'

Aug 24, 2026 03:37PM Insmed (INSM) PT Raised to $195 at Mizuho

Aug 24, 2026 07:03AM Japan approves Insmed's Brinsupri for lung disease treatment

Aug 10, 2026 06:40AM H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)

Aug 6, 2026 07:17AM Insmed (INSM) Tops Q2 EPS by 62c; offers guidance

Jul 28, 2026 09:44AM Cantor Fitzgerald Reiterates Overweight Rating on Insmed (INSM) Ahead of Q2 Results

Jul 21, 2026 06:12AM Raymond James sees potential for beats across biopharma coverage

Jul 20, 2026 05:01PM BMO Capital Starts Insmed (INSM) at Outperform

Jul 20, 2026 06:44AM H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)

Jul 17, 2026 07:20AM Insmed (INSM) Reiterated at Buy by Stifel After TPIP P2b Trial Data

Jul 16, 2026 07:02AM Insmed reports 12-month OLE data for TPIP in PAH patients

Jun 16, 2026 12:00PM Recent weakness provides an opportunity to buy this stock

Jun 16, 2026 06:41AM Insmed (INSM) PT Lowered to $192 at Mizuho

Jun 11, 2026 08:16PM NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance

Jun 10, 2026 07:02AM Insmed (INSM) Reiterated at Overweight by Cantor Fitzgerald

Jun 5, 2026 05:42AM Insmed (INSM) PT Lowered to $195 at RBC Capital

May 15, 2026 06:13AM Insmed (INSM) PT Lowered to $162 at Evercore ISI

May 13, 2026 01:06PM Insmed (INSM) PT Lowered to $185 at Truist Securities

May 12, 2026 12:02PM BofA Securities Reiterates Buy Rating on Insmed (INSM); 'pullback overdone'

May 8, 2026 11:00AM Buy the dip in this stock after a 23% earnings drop: Wall Street

May 7, 2026 07:39AM Insmed (INSM) Tops Q1 EPS by 20c

Apr 16, 2026 07:44AM Insmed (INSM) PT Raised to $230 at Guggenheim

Apr 14, 2026 06:33AM Insmed (INSM) PT Raised to $216 at RBC Capital

Apr 9, 2026 04:27PM Raymond James Starts Insmed (INSM) at Outperform, 'Brinsupri Launch at Peak Performance, With Room to Breathe'

Apr 8, 2026 09:22AM Insmed (INSM) PT Lowered to $212 at BofA Securities

Apr 8, 2026 07:13AM Insmed (INSM) Reiterated at Buy by Stifel Amid Returning Focus on Brinsupri Sales

Apr 8, 2026 07:13AM Insmed (INSM) PT Lowered to $220 at H.C. Wainwright

Apr 8, 2026 06:39AM Insmed (INSM) PT Lowered to $202 at Mizuho

Apr 7, 2026 04:55PM Truist Securities on Insmed (INSM): brensocatib in HS failure unsuprising, 'stock doesn't reflect any meaningful value for HS'

Apr 7, 2026 04:36PM After-hours movers: Levi, Greenbrier, Aehr Test and more

Apr 7, 2026 04:00PM Insmed (INSM) halted, news pending

Mar 30, 2026 08:47AM Stifel on Insmed (INSM): UTHR trial meeting endpoint removes overhang for INSM

Mar 30, 2026 08:43AM Leerink Partners on Insmed (INSM): competitor data gives positive readthrough, continues re-rate

Mar 30, 2026 08:29AM Jefferies on Insmed (INSM): UTHR data 'validates inhaled prostacyclin class in IPF,' INSM's TPIP potl BIC

Mar 30, 2026 04:13AM Morgan Stanley Upgrades Insmed (INSM) to Overweight

Mar 26, 2026 11:16AM Insmed (INSM) PT Raised to $245 at H.C. Wainwright

Mar 24, 2026 08:27AM Insmed (INSM) PT Raised to $206 at Mizuho following positive data

Mar 24, 2026 06:56AM Insmed (INSM) PT Raised to $208 at Stifel: Arikayce Peak Sales Revised Upwards

Mar 23, 2026 12:48PM Insmed (INSM) PT Raised to $213 at BofA Securities

Mar 23, 2026 12:07PM Insmed (INSM) PT Raised to $215 at Leerink Partners

Mar 23, 2026 12:07PM Insmed (INSM) PT Raised to $203 at RBC Capital

Mar 23, 2026 10:13AM Insmed (INSM) PT Raised to $230 at Jefferies

Mar 23, 2026 09:47AM Wolfe Research on Insmed (INSM): 'expect stock to converge toward PT over next few quarters'

Mar 23, 2026 08:48AM William Blair on Insmed (INSM): 'data overall supports approval'

Mar 23, 2026 08:06AM Stifel on Insmed (INSM): Topline data disclosure removes potential NT downside risk

Mar 23, 2026 07:01AM Insmed reports successful phase 3b trial for lung disease drug ARIKAYCE

Mar 22, 2026 10:00AM Jefferies says these are the best SMID-cap biotech stocks to buy

Feb 26, 2026 04:00PM Buy this pharma stock at current levels, Mizuho

View Older Stories